
Odaberite svoju etiketu
prikazano izravno na bočiciSemaglutide Oral
GLP-1 Oral
- Šalje se iz Njemačke
Narudžba
- DHL s praćenjem
- Diskretno pakiranje
4.6 od 5 na Trustpilotu73 recenzija
Traženo i kao: Semaglutid Oral · Semaglutid Tabletten
Na prvi pogled
Semaglutide Oral u brojkama
Ključni podaci iz našeg leksikona.
Cijeli članak u leksikonu- Class
- GLP-1 agonistoral
- Half-life
- longdosed daily
- Use
- Oral, fastedin mg/day
- Sizes
- 2 sizes3mg/25tabs, 7mg/25tabs
What studies show
The source in the lexiconPIONEER 1: oral semaglutide as monotherapy in type 2 diabetes (randomized) (opens in a new tab)
Aroda et al., Diabetes Care, 2019
Za Semaglutide Oral još nema laboratorijske analize. Glasaj za toDajte sami na testiranje, mi plaćamo polaSve laboratorijske analize
Znanje
Sve o Semaglutide Oral
Detaljne informacije uskoro.
Is this the same compound as the injection?
Yes. Semaglutide is a GLP-1 analogue with 94 percent sequence match to the body's own GLP-1. The tablet also contains SNAC, which enables absorption in the stomach. Because only a small part arrives, the milligram figures are higher than with the injection.
Is oral semaglutide approved?
Yes. ChEMBL lists semaglutide as an approved compound with first approval in 2017, the tablet has its own US label. On ClinicalTrials.gov a search for oral semaglutide gives 204 trials (as of 26 October 2026). Everything here is the state of research, not a recommendation.
Why fasted and with little water?
According to the label only about 0.4 to 1 percent reaches the blood. In studies in healthy people absorption was higher with little water than with a large glass. The longer nothing was eaten after the tablet, the more arrived. Hence the strict intake rule in the entry.
What did PIONEER 1 show?
703 people with type 2 diabetes using only diet and exercise received one of three doses or placebo. After 26 weeks HbA1c was 0.6 to 1.1 percentage points lower than with placebo. Weight fell clearly only on the highest study dose, by 2.3 kg more than on placebo.
What about the heart?
PIONEER 6 with 3,183 people showed that cardiovascular risk does not rise (3.8 versus 4.8 percent). SOUL with 9,650 people with vascular or kidney disease found 12.0 instead of 13.8 percent major events over about four years, so 14 percent fewer.
Which side effects are typical?
Mainly gastrointestinal complaints. According to the label 20 percent had nausea on the highest study dose, 6 percent on placebo. In addition there were abdominal pain, diarrhoea, decreased appetite, vomiting and constipation. The label also names rare risks such as pancreatitis and gallbladder problems.
Povezano
Srodni proizvodi
Semaglutide Oral